a formulation comprising , and process for preparing , improved oral dosage forms of 1 -- 3 -- naphthalen - 1 - yl ]- urea , a chemical entity with anti - inflammatory properties . granulation of 1 -- 3 -- naphthalen - 1 - yl ]- urea within specified ranges provides improved dissolution of 1 -- 3 -- naphthalen - 1 - yl ]- urea and oral bioavailability , as well as content uniformity . incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1 -- 3 -- naphthalen - 1 - yl ]- urea , such as beta - cyclodextrin provides enhanced stability of 1 -- 3 -- naphthalen - 1 - yl ]- urea , in particular in highly ionic environments . chipping and disintegration of tablets containing more than about 10 % betacyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at a temperature below 40 ° c .